Compare · MODD vs RMD
MODD vs RMD
Side-by-side comparison of Modular Medical Inc. (MODD) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MODD and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $29.46B, about 2355.8x MODD ($12.5M).
- Over the past year, MODD is down 88.9% and RMD is down 25.8% - RMD leads by 63.1 points.
- RMD has been more active in the news (7 items in the past 4 weeks vs 4 for MODD).
- RMD has more recent analyst coverage (25 ratings vs 0 for MODD).
- Company
- Modular Medical Inc.
- ResMed Inc.
- Price
- $2.34-6.40%
- $203.04+3.95%
- Market cap
- $12.5M
- $29.46B
- 1M return
- -43.07%
- +2.27%
- 1Y return
- -88.86%
- -25.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 7
- Recent ratings
- 0
- 25
Modular Medical Inc.
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest MODD
- Modular Medical Announces Formation of Pivot Innovation Council and Appointment of Robert Gabbay, MD, PhD, FACP as Chairman
- Modular Medical and IMO Health Launch Strategic Pilot to Enable Real Time Insulin Pump Patient Identification Into Electronic Health Records
- Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump
- Modular Medical Announces Completion of Research Initiative Indicating Strong Interest in Simpler Insulin Delivery
- SEC Form 4 filed by Director Vos Ellen O'Connor
- SEC Form 4 filed by Director Sheibley Philip Brent
- SEC Form 4 filed by Director Goldberg Jeff D
- Director Felsher Steven G was granted 25 shares, increasing direct ownership by 0.30% to 8,498 units (SEC Form 4)
- Director Volkart Carmen B was granted 110 shares, increasing direct ownership by 14% to 916 units (SEC Form 4)
- Director Desisto Duane M was granted 83 shares, increasing direct ownership by 0.97% to 8,627 units (SEC Form 4)
Latest RMD
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)